Clinical Trial Update: A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating monthly subcutaneous continuous erythropoietin receptor activator (CERA) for anemia in predialysis chronic kidney disease patients; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia in Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 3 | Status: COMPLETED | Results posted: 2016-04-04